AutoZone, Inc.

AZO Q4 2026

Reported: 2026-09-24

AutoZone shares rose 1.4%, a relatively muted reaction to mixed results: total sales grew 5.6%, but same-store sales increased just 1.5% and domestic DIY comps declined 0.6%. Management said the domestic business was below expectations and forecast relatively flat same-store sales in Q1.

Key takeaways

Total company same-store sales grew 1.5% on a constant-currency basis; domestic comps were up 1.6%.
Domestic DIY comps fell 0.6%, as roughly 5% average-ticket growth was offset by traffic declines. Domestic retail comps were essentially flat in August after running negative earlier in the quarter.
Domestic commercial sales grew 8.6% in Q4 and nearly 11% for FY 2026, supported by improved inventory availability and hub coverage.
Q1 same-store sales are expected to be relatively flat, with average-ticket growth around 5%.
AutoZone opened 374 stores in FY 2026, up from 304 the prior year; Q4 EPS rose 15.1%, including a $96 million ($4.43 per share) benefit from IEEPA tariff refunds.

View recap

Henry Boot PLC

BOOT.L Q2 2026

Reported: 2026-09-24

Henry Boot reported a weaker-than-expected performance by its own assessment, with revenue down 19%, an operating loss and higher gearing; the stock was roughly flat, down 0.4%. The interim dividend suspension and ongoing work to amend full-year covenant requirements underscore the near-term balance-sheet pressure.

Key takeaways

Revenue fell 19% to just below £81 million, reflecting lower transactional activity across all markets.
The group recorded a £3.9 million operating loss; land promotion was the main driver of the year-on-year decline in operating profit.
Net debt ended the period at £133 million and gearing rose to 33%. Management expects gearing to ease after planned second-half disposals.
The company will not pay an interim dividend, citing higher gearing and the second-half weighting of its performance.
Henry Boot has agreed to increase its bank facility to £165 million through December 31; discussions continue on potential amendments to full-year covenants.

View recap

Clover Corporation Limited

CLV.AX Q4 2026

Reported: 2026-09-24

Clover’s shares rose 5.8% after FY26 revenue came in at AUD 97.4 million, slightly above the company’s AUD 92–96 million guidance range, alongside higher margins and profit. The result was supported by increased ARA demand and a richer product mix, though inventory growth absorbed cash and the company gave no specific forward guidance in the excerpt.

Key takeaways

Revenue rose 13% to AUD 97.4 million; gross margin increased 4 percentage points to 35.5%.
EBITDA was AUD 17 million, up AUD 4.7 million year on year; NPAT rose 50% to AUD 10.5 million.
Higher ARA powder demand, particularly from the infant formula market, and a more diversified product mix supported growth and margins.
Net working capital increased AUD 7.5 million to AUD 49.8 million, driven by a AUD 19.8 million increase in inventory; management said this was to meet forecast demand and reflects long supply-chain lead times.
Clover ended the year with AUD 7.2 million in cash and no interest-bearing liabilities; the board declared a final fully franked dividend of AUD 0.0125 per share.

View recap

Craneware plc

CRW.L Q4 2026

Reported: 2026-09-24

Craneware shares rose 5.6% after earnings. The company acknowledged a disappointing FY26 slowdown in 340B transactional revenue, but highlighted recurring revenue of $185 million and said it is resetting FY27 expectations to its ARR base while it assesses uncertainty from 340B and a cybersecurity incident.

Key takeaways

Management attributed the late-year 340B slowdown to manufacturers restricting the supply of drugs at 340B pricing.
Recurring revenue was $185 million; net revenue retention was 100%, and customer retention was greater than 90%.
The company reported strong EBITDA performance and cash generation, but did not provide figures in the excerpt.
Craneware is rebasing FY27 numbers to its ARR level and undertaking a comprehensive cost-base review.
Following a July cyber incident, the company said threat actors were removed within 24 hours and operations continued. Some staff, customer, and patient details were among the files taken; the full financial impact remains under assessment.

View recap

PureTech Health plc

PRTC.L Q2 2026

Reported: 2026-09-24

PureTech shares fell 4.1% after the results, with the clearest negative signal being a material downgrade to estimated future proceeds from its remaining Cobenfy economic rights. Management put those potential proceeds at approximately $50 million based on analyst consensus, while emphasizing the value of the earlier Royalty Pharma transaction.

Key takeaways

PureTech ended the first half with $220 million in cash, cash equivalents and short-term investments, and said its operational runway is expected to extend at least through the end of 2028.
Celea raised $180 million in external financing and initiated its global Phase III SURPASS-IPF trial; PureTech retains a 35.4% equity interest plus royalties, milestones and sublicense income rights.
Seaport completed its NASDAQ IPO in May, raising $250 million in gross proceeds. PureTech holds a 31.2% stake, valued at approximately $360 million as of September 18, 2026, and retains royalty and milestone rights.
Gallop received Fast Track designation for relapsed/refractory high-risk MDS. PureTech owns 100% and intends to seek external capital before starting the Phase II STRIDE-MDS trial.
The approximately $50 million estimate for future Cobenfy proceeds is based on analyst consensus and represents a material downgrade from PureTech’s last update at full year. PureTech said it has generated more than $1 billion from its collective Karuna and Cobenfy economics.

View recap

Smiths Group plc

SMIN.L Q4 2026

Reported: 2026-09-24

The 7.5% share-price gain suggests investors welcomed the outlook: Smiths expects around 4% organic revenue growth in FY27 and further margin progress into its 21%–23% target range. FY26 growth was modest, with organic revenue up 1.2%, but margins expanded and cash conversion remained high.

Key takeaways

FY26 organic revenue rose 1.2% to £1.9bn; headline operating profit increased 1.9% organically to £399m.
Headline operating margin expanded 20 basis points to 20.6%, despite Middle East disruption, tariffs, lower volumes and growth investment.
Headline EPS for continuing operations increased 6% to 86.8p; operating cash conversion was 96%. The proposed full-year dividend is 48.5p, up 5.4%.
Growth faced pressure from Middle East disruption, which reduced John Crane revenue by £20m, and weakness in U.S. residential construction, alongside destocking and project phasing in Thermal Solutions.
For FY27, management expects around 4% organic revenue growth and further margin progress. It says the medium-term 5%–7% growth target is achievable sooner, while near-term market conditions remain challenging.

View recap

Earnings Recaps

AutoZone, Inc.

Henry Boot PLC

Clover Corporation Limited

Craneware plc

PureTech Health plc

Smiths Group plc

Community

Earnings Recaps

AutoZone, Inc.

Henry Boot PLC

Clover Corporation Limited

Craneware plc

PureTech Health plc

Smiths Group plc

Community

Trending This Week

Notifications